SubjectWell

Headquartered in Texas, SubjectWell supports clinical research sites with the patient recruitment process, focusing on reaching patients who have no prior experience of clinical trials. The company’s process starts with building awareness and patient education, followed by patient outreach and a guided enrollment process.

SubjectWell offers a risk-free pricing model that only charges customers for patients that sign up and enter the randomization stage of a clinical trial. The company claims that this aligns the company’s goals with its clients, in addition to providing clarity on the acquisition cost per patient for clinical research sites.

When engaging with potential customers, SubjectWell provides a detailed proposal, including a recruitment assessment that outlines the potential patient population, breakdowns by demographics, and pricing. This assessment is provided free of charge to potential customers.

In April 2024 the company was acquired by WindRose Health Investors, a New York-based healthcare private equity firm, for an undisclosed sum. The current management of SubjectWell at the time of the acquisition was kept on to continue to manage the company. Post-acquisition, WindRose planned to inject additional capital into SubjectWell to foster its expansion. The focus was on accelerating the development of existing and new solutions while leveraging SubjectWell's marketplace to assist healthcare companies in need of qualified candidates for clinical trials.

Key customers and partnerships

As of June 2024, SubjectWell claims to have supported clinical trials for 19 out of the top 20 pharmaceutical companies in the world. Additionally, its platform was available across 6 continents and registered 300,000+ patients monthly. The company further noted that from its pool of registered patients, it had helped 10,000+ patients enroll in over 700 studies as randomized participants, facilitated 350,000+ referrals, and assisted 4,700+ sites.